British Journal of Clinical Pharmacology · 2019 · 25 citations · 20 references
Life SciencesImmunologyPharmacologyEpidemiologyHypersensitivityImmunogeneticsDrug AllergyEosinophilic DisordersHla MatchingHla TypingIndigenous HealthMolecular TypingAllele FrequencyHla Allele Frequency DistributionHla Allele PolymorphismHla Genotype AssociationsHla Risk AllelesHla-associated Adverse Drug ReactionsHuman Leukocyte Antigen GenotypePhenytoin Therapy
Phenytoin drug reaction with eosinophilia and systemic symptoms (DRESS) in 3 Aboriginal Australians positive for HLA-B*56:02 has been previously reported. We report the allele frequency of HLA-B*56:02 in 2 South Australian populations, 1 Aboriginal (4.8%, 95% confidence interval 2.4-7.8%) and the other European (0%). We compared the frequency with publicly available information on HLA-B*56:02 status in other Indigenous Australian (n = 4) and European Australian cohorts (n = 1). In the Indigenous Australian cohorts, HLA-B*56:02 allele frequency ranged from 1.3 to 19%. We also describe an additional case of phenytoin DRESS (RegiSCAR DRESS score 7) in an Aboriginal Australian that was associated with HLA-B*56:02 and with CYP2C9*1/*3 genotype. In Aboriginal Australians, phenytoin DRESS appears distinctly linked to HLA-B*56:02 with an allele carriage rate substantially higher than in Europeans, but also with considerable regional variation. Investigations of human leucocyte antigen and other contributing genes and severe adverse drug reactions in understudied non-European populations are required to optimize safe medication use and inform risk mitigation strategies.
20
Sylvia H. Kardaun, Peggy Sekula, L. Valeyrie‐Allanore et al. · British Journal of Dermatology · 2013 · 980 citations
Aboriginal mitogenomes reveal 50,000 years of regionalism in Australia
Raymond Tobler, Adam B. Rohrlach, Julien Soubrier et al. · Nature · 2017 · 367 citations · Full text